Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao LP, Caballero Berrocal JC, Sala C, Maggioni G, Bernardi M, Di Grazia C, Vago L, Rivoli G, Borin L, D'Amico S, Tentori CA, Ubezio M, Campagna A, Russo A, Mannina D, Lanino L, Chiusolo P, Giaccone L, Voso MT, Riva M, Oliva EN, Zampini M, Riva E, Nibourel O, Bicchieri M, Bolli N, Rambaldi A, Passamonti F, Savevski V, Santoro A, Germing U, Kordasti S, Santini V, Diez-Campelo M, Sanz G, Sole F, Kern W, Platzbecker U, Ades L, Fenaux P, Haferlach T, Castellani G, Della Porta MG. Sauta E, et al. Among authors: riva e, riva m. J Clin Oncol. 2023 May 20;41(15):2827-2842. doi: 10.1200/JCO.22.01784. Epub 2023 Mar 17. J Clin Oncol. 2023. PMID: 36930857 Free PMC article.
The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
Molteni A, Riva M, Borin L, Bernardi M, Pelizzari AM, Freyrie A, Della Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, Cairoli R, Morra E. Molteni A, et al. Among authors: riva m. Leuk Res. 2016 Mar;42:21-7. doi: 10.1016/j.leukres.2016.01.006. Epub 2016 Jan 18. Leuk Res. 2016. PMID: 26852003
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.
Piciocchi A, Sargentini V, Cotugno F, Bontempi K, Beltrami G, Di Tucci AA, Riva M, Quaresmini G, Vallisa D, Finelli C, Borin L, Fazi P, Vignetti M, Angelucci E. Piciocchi A, et al. Among authors: riva m. Eur J Haematol. 2019 May;102(5):442-443. doi: 10.1111/ejh.13222. Epub 2019 Mar 13. Eur J Haematol. 2019. PMID: 30776156 No abstract available.
SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience.
Mossuto S, Attardi E, Alesiani F, Angelucci E, Balleari E, Bernardi M, Binotto G, Bosi C, Calvisi A, Capodanno I, Carbone A, Castelli A, Cerrano M, Ciancia R, Cilloni D, Clavio M, Clissa C, Crisà E, Crugnola M, Della Porta MG, Di Renzo N, Di Veroli A, Fattizzo R, Fava C, Fenu S, Ferrara IL, Fianchi L, Filì C, Finelli C, Giai V, Frattini F, Gaidano V, Guaragna G, Gumenyuk S, Latagliata R, Mancini S, Messa E, Molteni A, Musto P, Niscola P, Oliva E, Palumbo GA, Pelizzari A, Pilo F, Poloni A, Riva M, Rivellini F, Sarlo C, Sciumé M, Secchi R, Selleri C, Tafuri A, Santini V. Mossuto S, et al. Among authors: riva m. Hemasphere. 2020 Sep 23;4(5):e483. doi: 10.1097/HS9.0000000000000483. eCollection 2020 Oct. Hemasphere. 2020. PMID: 33062948 Free PMC article. No abstract available.
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.
Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca E, Chiereghin C, Di Nanni N, Gnocchi M, Zampini M, Rossi M, Maggioni G, Termanini A, Angelucci E, Bernardi M, Borin L, Bruno B, Bonifazi F, Santini V, Bacigalupo A, Voso MT, Oliva E, Riva M, Ubezio M, Morabito L, Campagna A, Saitta C, Savevski V, Giampieri E, Remondini D, Passamonti F, Ciceri F, Bolli N, Rambaldi A, Kern W, Kordasti S, Sole F, Palomo L, Sanz G, Santoro A, Platzbecker U, Fenaux P, Milanesi L, Haferlach T, Castellani G, Della Porta MG. Bersanelli M, et al. Among authors: riva m. J Clin Oncol. 2021 Apr 10;39(11):1223-1233. doi: 10.1200/JCO.20.01659. Epub 2021 Feb 4. J Clin Oncol. 2021. PMID: 33539200 Free PMC article.
Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.
Oliva EN, Latagliata R, Sabattini E, Mammì C, Cuzzola M, D'Errigo MG, Cannatà MC, Bova I, Capodanno I, Palumbo GA, Pane F, Reda G, Fianchi L, Riva M, Poloni A. Oliva EN, et al. Among authors: riva m. Am J Blood Res. 2021 Aug 15;11(4):417-426. eCollection 2021. Am J Blood Res. 2021. PMID: 34540351 Free PMC article.
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Lanino L, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Consagra A, Musto P, Cilloni D, Oliva EN, Palmieri R, Poloni A, Califano C, Capodanno I, Itri F, Elena C, Fozza C, Pane F, Pelizzari AM, Breccia M, Di Bassiano F, Crisà E, Ferrero D, Giai V, Barraco D, Vaccarino A, Griguolo D, Minetto P, Quintini M, Paolini S, Sanpaolo G, Sessa M, Bocchia M, Di Renzo N, Diral E, Leuzzi L, Genua A, Guarini A, Molteni A, Nicolino B, Occhini U, Rivoli G, Bono R, Calvisi A, Castelli A, Di Bona E, Di Veroli A, Ferrara F, Fianchi L, Galimberti S, Grimaldi D, Marchetti M, Norata M, Frigeni M, Sancetta R, Selleri C, Tanasi I, Tosi P, Turrini M, Giordano L, Finelli C, Pasini P, Naldi I, Santini V, Della Porta MG; Fondazione Italiana Sindromi Mielodisplastiche (FISiM) Clinical network (https://www.fisimematologia.it/). Lanino L, et al. Among authors: riva m. Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24. Am J Hematol. 2023. PMID: 37222267 Free article. No abstract available.
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisà E, Capodanno I, Salutari P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Iannì G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P, Germing U, Ricco A, Palumbo GA, Impera S, Di Renzo N, Rivellini F, Buccisano F, Stamatoullas-Bastard A, Liberati AM, Candoni A, Delfino IM, Arcadi MT, Cufari P, Rizzo L, Bova I, D'Errigo MG, Zini G, Latagliata R. Oliva EN, et al. Among authors: riva m. J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9. J Clin Oncol. 2023. PMID: 37294914 Free PMC article. Clinical Trial.
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination-Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda.
Rossi G, Borlenghi E, Zappasodi P, Lussana F, Bernardi M, Basilico C, Molteni A, Lotesoriere I, Turrini M, Frigeni M, Fumagalli M, Cozzi P, Gigli F, Cattaneo C, Fracchiolla NS, Riva M, Martini G, Mancini V, Cairoli R, Todisco E. Rossi G, et al. Among authors: riva m. Cancers (Basel). 2024 Jan 16;16(2):386. doi: 10.3390/cancers16020386. Cancers (Basel). 2024. PMID: 38254875 Free PMC article.
1,148 results